Savara (SVRA) Research & Development (2010 - 2026)
Savara (SVRA) reported Research & Development of $23.4 million for Q1 2026, up 22.13% year-over-year from $19.2 million in Q1 2025, and up 11.94% quarter-over-quarter from $20.9 million in Q4 2025.
Savara (SVRA) Research & Development (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Research & Development data on file, last reported at $23.4 million in Q1 2026.
- Research & Development for Q1 2026 came in at $23.4 million, up 22.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.6 million (up 6.55% YoY), and the FY2025 annual result was $81.4 million, up 4.33% from the prior year.
- Research & Development grew to $23.4 million in Q1 2026 per SVRA's latest filing, from $20.9 million in the prior quarter.
- Over five years, Research & Development peaked at $23.4 million in Q1 2026 and troughed at $5.7 million in Q1 2022.
- A 5-year average of $15.0 million and a median of $16.8 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development slipped 25.1% in 2022, then surged 97.7% in 2024.
- A 5-year view of Research & Development shows it stood at $7.6 million in 2022, then soared by 67.14% to $12.7 million in 2023, then jumped by 82.76% to $23.3 million in 2024, then dropped by 10.27% to $20.9 million in 2025, then climbed by 11.94% to $23.4 million in 2026.
- Business Quant data shows SVRA's Research & Development at $23.4 million in Q1 2026, $20.9 million in Q4 2025, and $20.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 23.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.40 Mn |
| Dec 31, 2025 | 20.90 Mn |
| Sep 30, 2025 | 20.59 Mn |
| Jun 30, 2025 | 20.75 Mn |
| Mar 31, 2025 | 19.16 Mn |
| Dec 31, 2024 | 23.29 Mn |
| Sep 30, 2024 | 20.31 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 16.81 Mn |
| Dec 31, 2023 | 12.75 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 8.91 Mn |
| Mar 31, 2023 | 8.74 Mn |
| Dec 31, 2022 | 7.63 Mn |
| Sep 30, 2022 | 8.15 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 5.68 Mn |
| Dec 31, 2021 | 7.62 Mn |
| Sep 30, 2021 | 6.53 Mn |
| Jun 30, 2021 | 7.25 Mn |